摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(E)-Ceftriaxone Disodium

中文名称
——
中文别名
——
英文名称
(E)-Ceftriaxone Disodium
英文别名
disodium;(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(E)-Ceftriaxone Disodium化学式
CAS
——
化学式
C18H16N8Na2O7S3
mdl
——
分子量
598.6
InChiKey
FDRNWTJTHBSPMW-BBJOQENWSA-L
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -9.16
  • 重原子数:
    38
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    297
  • 氢给体数:
    2
  • 氢受体数:
    14

ADMET

毒理性
  • 肝毒性
静脉注射头孢曲松与3%至46%的患者发生胆泥形成有关。儿童的发生率可能高于成人,并且与较高剂量和较长的治疗疗程以及可能的禁食或脱水有关。这种综合征被称为“假性结石病”,因为泥沙和结石主要由头孢曲松组成,停药后会自行溶解,这表明可以避免手术。大多数病例发生时几乎没有或没有症状。据报道,多达5%的患者在发展成假性结石病时会出现胆绞痛的明显症状。通常情况下,即使有胆绞痛,血清酶和胆红素水平仍然正常,但在罕见情况下,可能会有胆汁淤积性黄疸或胆石性胰腺炎,这可能会很严重并需要手术治疗。胆泥和胆囊疾病的症状可能在开始治疗后的几天内出现,但通常在停用头孢曲松后会迅速缓解,尽管泥沙和胆结石可能会在超声波检查中持续几个月。 头孢曲松还可能导致一种与其他头孢菌素相似的免疫过敏性胆汁淤积性肝炎。这种反应是特异质性的,非常罕见。在开始治疗后的1到4周内,会出现腹痛、恶心、瘙痒和黄疸的症状,并在停用抗生素后的1到2周内可能恶化。血清酶升高和免疫过敏性特征如发热、皮疹和嗜酸性粒细胞增多的胆汁淤积模式很常见。损伤通常是轻微的和自限性的。 可能性评分:B(头孢曲松是临床上明显肝损伤的非常可能原因,也可能导致胆泥和“假性结石病”,这是由胆汁中头孢曲松的结晶引起的)。
Parenteral administration of ceftriaxone has been associated with development of biliary sludge in 3% to 46% of patients. The incidence may be higher in children than adults and is associated with higher doses and longer courses of treatment and possibly with fasting or dehydration. The syndrome is referred to as “pseudolithiasis” as the sludge and stones consist largely of ceftriaxone and they resolve spontaneously when the drug is stopped, indicating that surgery can be avoided. Most cases occur with minimal or no symptoms. Frank symptoms of cholecystitis are reported in up to 5% of patients who develop pseudo-lithiasis. Typically, serum enzymes and bilirubin levels remain normal even with biliary colic, but in rare instances there is cholestatic jaundice or gallstone pancreatitis that can be severe and require surgical intervention. Sludge and symptoms of gallbladder disease can arise within a few days of starting therapy, but typically resolve rapidly once ceftriaxone is stopped, although sludge and gallstones may be detectable by ultrasound for several months. Ceftriaxone can also lead to an immunoallergic form of cholestatic hepatitis similar to what has been described with other cephalosporins. This reaction is idiosyncratic and is very rare. Symptoms of abdominal pain, nausea, pruritis and jaundice arise within 1 to 4 weeks of initiation of therapy and may worsen for 1 to 2 weeks after stopping the antibiotic. A cholestatic pattern of serum enzyme elevations and immunoallergic features of fever, rash and eosinophilia are common. The injury is usually mild and self-limited. Likelihood score: B (ceftriaxone is a very likely cause of clinically apparent liver injury and can also lead to biliary sludge and “pseudolithiasis” caused by crystallization of ceftriaxone in bile present in the gallbladder or biliary tree).
来源:LiverTox
毒理性
  • 在妊娠和哺乳期间的影响
◉ 母乳喂养期间使用概要:有限的信息表明,头孢曲松在乳汁中产生的水平较低,预计不会对哺乳婴儿造成不良影响。偶尔有报道指出,头孢菌素类药物可能会破坏婴儿的胃肠道菌群,导致腹泻或鹅口疮,但这些影响尚未得到充分评估。头孢曲松对哺乳母亲是可接受的。 ◉ 对哺乳婴儿的影响:一位仅以母乳喂养其52天大婴儿的母亲患上了软组织感染。她接受了静脉注射太古霉素,每次400毫克,每12小时一次,共3次,然后每天400毫克,总共5天,静脉注射头孢曲松每天1克,外用莫匹罗星乳膏每天两次。仔细的随访表明,她的婴儿没有出现不良反应。 ◉ 对泌乳和母乳的影响:截至修订日期,未找到相关的已发布信息。
◉ Summary of Use during Lactation:Limited information indicates that ceftriaxone produce low levels in milk, which are not expected to cause adverse effects in breastfed infants. Occasionally disruption of the infant's gastrointestinal flora, resulting in diarrhea or thrush have been reported with cephalosporins, but these effects have not been adequately evaluated. Ceftriaxone is acceptable in nursing mothers. ◉ Effects in Breastfed Infants:A mother who was exclusively nursing her 52-day-old infant developed a soft-tissue infection. She was treated with intravenous teicoplanin 400 mg every 12 hours for 3 doses, then 400 mg daily for 5 days total, intravenous ceftriaxone 1 gram daily, topical mupirocin cream twice daily. A careful follow-up indicated that her infant had no adverse effects. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.
来源:Drugs and Lactation Database (LactMed)

反应信息

  • 作为反应物:
    描述:
    (E)-Ceftriaxone Disodium间氯过氧苯甲酸 生成 disodium;(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-5,8-dioxo-5λ4-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
    参考文献:
    名称:
    MONTAVON, M.;REINER, R.
    摘要:
    DOI:
  • 作为产物:
    参考文献:
    名称:
    MONTAVON, M.;REINER, R.
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • [EN] A PROCESS FOR THE PREPARATION OF A CEPHALOSPORIN ANTIBIOTIC<br/>[FR] PROCEDE DE PREPARATION D'UN ANTIBIOTIQUE A CEPHALOSPORINE
    申请人:ORCHID CHEMICALS & PHARM LTD
    公开号:WO2004111059A1
    公开(公告)日:2004-12-23
    An improved process for the preparation of ceftriaxone sodium comprising the steps of : i) reacting the 3-cephem derivative of formula (II) with halo acid derivative of formula (III) wherein X represents halogen and Y represent halogen in the presence of silylating agent and methylene chloride at -25 to 10 °C, to produce (IV), ii) quenching the reaction by pouring the reaction mixture into water or in a aqueous solution of sodium carbonate, iii) preparing sodium salt solution of (IV) by adding sodium carbonate and separating the organic layer, iv) cyclizing the sodium salt of (IV) in the aqueous solution with thiourea at a temperature in the range of 0 to 30 °C, v) adjusting the pH to 1.5 to 2.5 to precipitate the ceftriaxone free acid, vi) converting the ceftriaxone free acid to sodium salt using sodium-2-ethyl hexanoate in water and vii) precipitating and isolating the ceftriaxone sodium.
    一种改进的头孢曲松钠制备方法,包括以下步骤:i) 在硅化剂和氯代酸衍生物的存在下,将式(II)的3-头孢烯衍生物与式(III)的卤素酸衍生物(其中X代表卤素,Y代表卤素)在-25至10°C的温度下在氯化甲烷中反应,生成(IV),ii) 通过将反应混合物倒入水或碳酸钠溶液中来停止反应,iii) 通过加入碳酸钠并分离有机层来制备(IV)的钠盐溶液,iv) 在0至30°C范围内与硫脲在水溶液中使(IV)的钠盐环化,v) 将pH调整为1.5至2.5以沉淀头孢曲松游离酸,vi) 使用水中的2-乙基己酸钠将头孢曲松游离酸转化为钠盐,vii) 沉淀和分离头孢曲松钠。
  • MONTAVON, M.;REINER, R.
    作者:MONTAVON, M.、REINER, R.
    DOI:——
    日期:——
  • Process for the preparation of a cephalosporin antibiotic
    申请人:Deshpande Balwant Pandurang
    公开号:US20050027118A1
    公开(公告)日:2005-02-03
    An improved process for the preparation of ceftriaxone sodium comprising the steps of: i) reacting the 3-cephem derivative of formula (II) with halo acid derivative of formula (III) wherein X represents halogen and Y represent halogen in the presence of silylating agent and methylene chloride at −25 to 10° C., to produce (IV), ii) quenching the reaction by pouring the reaction mixture into water or in a aqueous solution of sodium carbonate, iii) preparing sodium salt solution of (IV) by adding sodium carbonate and separating the organic layer, iv) cyclizing the sodium salt of (IV) in the aqueous solution with thiourea at a temperature in the range of 0 to 30° C., v) adjusting the pH to 1.5 to 2.5 to precipitate the ceftriaxone free acid, vi) converting the ceftriaxone free acid to sodium salt using sodium-2-ethyl hexanoate in water and vii) precipitating and isolating the ceftriaxone sodium.
  • US4717768A
    申请人:——
    公开号:US4717768A
    公开(公告)日:1988-01-05
  • US4876351A
    申请人:——
    公开号:US4876351A
    公开(公告)日:1989-10-24
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物